Novartis AG stock (CH0012005267): Global pharma leader navigates patent cliffs

Novartis AG, the Swiss pharmaceutical giant, continues to drive growth through its innovative drug portfolio amid ongoing patent expirations. US investors track the company's Sandoz spin-off and key pipeline assets for long-term value.

Novartis AG maintains its position as a leading global pharmaceutical company, focusing on innovative medicines in areas like cardiovascular, immunology, neuroscience, and oncology. The company reported full-year 2025 revenue of $46.3 billion, up 10% in constant currencies, driven by strong performances from drugs like Entresto and Kesimpta, according to Novartis media release as of Feb 4, 2026.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Novartis AG
• Sector/industry: Pharmaceuticals / Biotechnology
• Headquarters/country: Basel, Switzerland
• Core markets: US, Europe, Asia
• Key revenue drivers: Innovative medicines, generics via Sandoz
• Home exchange/listing venue: SIX Swiss Exchange (NOVN), NYSE (NVS)
• Trading currency: CHF (SIX), USD (NYSE)

Novartis AG: core business model

Novartis AG operates as a multinational pharmaceutical corporation headquartered in Basel, Switzerland. Its business model centers on research-driven innovation, developing and commercializing patented medicines across multiple therapeutic areas. The company spun off its generics and biosimilars unit Sandoz in 2023, allowing Novartis to focus on high-margin innovative drugs, according to Novartis investor relations as of 2026.

This strategic shift positions Novartis as a pure-play innovator, with core growth platforms in cardiovascular-renal-metabolic, immunology, neuroscience, and oncology. The company invests heavily in R&D, spending approximately 18% of sales on innovation, supporting a pipeline of over 40 new molecular entities and indications as of early 2026.

Main revenue and product drivers for Novartis AG

Key revenue drivers include blockbuster drugs like Entresto (sacubitril/valsartan) for heart failure, which generated $6.2 billion in 2025 sales, up 25% year-over-year, and Kesimpta (ofatumumab) for multiple sclerosis, contributing $5.1 billion. Oncology portfolio, led by Kisqali (ribociclib), added $4.8 billion, per the full-year 2025 results published Feb 4, 2026, by Novartis as of Feb 4, 2026.

Emerging products like Fabhalta (iptacopan) for paroxysmal nocturnal hemoglobinuria and Scemblix (asciminib) for chronic myeloid leukemia are gaining traction, with Fabhalta posting $1.2 billion in peak sales potential. Novartis derives about 40% of revenue from the US market, making it highly relevant for American investors tracking Big Pharma exposure.

Industry trends and competitive position

The global pharmaceutical industry faces patent cliffs, biosimilar competition, and pricing pressures, particularly in the US under ongoing drug price negotiation frameworks. Novartis navigates these with a robust pipeline and strategic acquisitions, maintaining a top-5 position by market cap among pharma peers like Roche, Pfizer, and Merck.

In immunology and oncology, Novartis competes with leaders like Johnson & Johnson and Bristol Myers Squibb, leveraging differentiated mechanisms such as BTK inhibitors and CDK4/6 advancements. Its focus on precision medicine aligns with sector trends toward targeted therapies, per industry reports from IQVIA dated 2025.

Why Novartis AG matters for US investors

Novartis holds a significant US footprint, with over 40% of sales from North America and a NYSE listing under ticker NVS. US investors benefit from exposure to Europe's R&D efficiency combined with strong American market demand for cardiology and oncology drugs. The stock offers dividend yield around 3.5% as of early 2026, appealing for income-focused portfolios.

Conclusion

Novartis AG demonstrates resilience through its innovative portfolio and strategic focus post-Sandoz spin-off, with 2025 results underscoring growth in key franchises. While patent expirations pose challenges, the pipeline offers upside potential. US investors monitor upcoming catalysts like Fabhalta expansions and Q1 2026 earnings for continued momentum.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.